J. Jakubowski

发表

Point-of-Care Platelet Reactivity Determination with VerifyNow-P2Y12 following Administration of Clopidogrel or Prasugrel: Data from a Real-World, Clinical Care Inpatient Setting

J. Meyers, S. Candrilli, J. Bae, 2014, Hospital practice.

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem

G. Stone, A. Kastrati, F. Neumann, 2012, Journal of the American College of Cardiology.

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

S. James, D. Erlinge, C. Varenhorst, 2014, Thrombosis and Haemostasis.

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration

K. Winters, J. Jakubowski, J. Brandt, 2008, Thrombosis and Haemostasis.

Chapter 11. Future Antithrombotic Therapy

D. Sall, J. Jakubowski, Gerald F. Smith, 1992 .

Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes

A. Balduini, M. Currao, J. Jakubowski, 2012, Haematologica.

Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease.

A. Chishti, A. Frelinger, A. J. Gerrits, 2017, Thrombosis Research.

The active metabolite of prasugrel, R-138727, improves cerebral blood flow and reduces cerebral infarction and neurologic deficits in a non-human primate model of acute ischaemic stroke.

J. Jakubowski, M. Mizuno, A. Sugidachi, 2016, European journal of pharmacology.

Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel

R. Storey, J. Jakubowski, H. Judge, 2010, Journal of thrombosis and haemostasis : JTH.

Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occlusive diseases.

M. Hashimoto, J. Jakubowski, T. Ogawa, 2009, European journal of pharmacology.

Clopidogrel poor responders: An objective definition based on Bayesian classification

K. Winters, G. Weerakkody, J. Jakubowski, 2007, Platelets.

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

E. Vicaut, D. Dudek, T. Costigan, 2013, The New England journal of medicine.

Platelet size and age determine platelet function independently

C. Thompson, P. G. Quinn, J. Jakubowski, 1984 .

Platelet size and age determine platelet function independently.

C. Thompson, P. G. Quinn, J. Jakubowski, 1984, Blood.

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

K. Ataga, A. Kutlar, K. Winters, 2013, Journal of Hematology & Oncology.

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.

K. Winters, A. Frelinger, S. Jurcevic, 2014, Thrombosis research.

Prasugrel in Children With Sickle Cell Disease: Pharmacokinetic and Pharmacodynamic Data From an Open-label, Adaptive-design, Dose-ranging Study

K. Winters, C. Quinn, M. Heeney, 2015, Journal of pediatric hematology/oncology.

Interaction of the active metabolite of prasugrel, R‐138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor

I. von Kügelgen, J. Jakubowski, I. Kügelgen, 2008, Journal of thrombosis and haemostasis : JTH.

Relationship of Platelet Reactivity With Bleeding Outcomes During Long‐Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non‐ST‐Segment Elevation Acute Coronary Syndromes

Deepak L. Bhatt, D. Prabhakaran, P. Armstrong, 2016, Journal of the American Heart Association.

Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?

E. Ohman, J. Cornel, K. Huber, 2012, Thrombosis and Haemostasis.

Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function

R. Storey, J. Jakubowski, A. Sugidachi, 2010, Thrombosis and Haemostasis.

Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis.

J. Jakubowski, M. Mizuno, A. Sugidachi, 2015, Thrombosis research.

Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients

M. Effron, H. Fisher, D. Angiolillo, 2014, Thrombosis and Haemostasis.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study

T. Costigan, M. Effron, D. Angiolillo, 2012, Thrombosis and Haemostasis.

A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel

A. Kastrati, A. Schömig, B. Baker, 2013, Platelets.

Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor

M. Rumpf, A. Fender, R. Kelsch, 2018, Journal of thrombosis and haemostasis : JTH.

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply

A. Michelson, A. L. Frelinger, A. J. Gerrits, 2018, Journal of thrombosis and haemostasis : JTH.

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.

D. Foley, Junxiang Luo, S. James, 2012, Journal of the American College of Cardiology.

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.

T. Costigan, M. Effron, D. Angiolillo, 2010, Journal of the American College of Cardiology.

Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial

E. Antman, E. Braunwald, Richard Cairns, 2007, Circulation.

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses

R. Storey, J. Jakubowski, A. Sugidachi, 2008, Platelets.

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

T. Costigan, M. Effron, N. Kleiman, 2013, Thrombosis and Haemostasis.

Coronary heart disease Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

A. Siegbahn, L. Wallentin, T. Jernberg, 2006 .

Effects of insulin and prior exercise on prostaglandin release from perfused rat muscle. Evidence that prostaglandins do not mediate changes in glucose uptake.

A. Zorzano, N. Ruderman, J. Jakubowski, 1986, The Biochemical journal.

Ethanol enhances the inhibitory effect of an oral GPIIb/IIIa antagonist on human platelet function.

M. J. Fisher, R. Kinlough-Rathbone, M. Packham, 2002, The Journal of laboratory and clinical medicine.

Current Antiplatelet Therapy

H. Weisman, R. Jordan, J. Jakubowski, 1999 .

Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine coronary artery.

C. V. Jackson, J. Jakubowski, T. Shetler, 1998, Thrombosis research.

Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates.

R. Jordan, D. Herrington, M. Adams, 1998, Arteriosclerosis, thrombosis, and vascular biology.

The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.

M. Furman, A. Michelson, K. Winters, 2008, Journal of thrombosis and haemostasis : JTH.

The active metabolite of prasugrel inhibits adenosine diphosphate‐ and collagen‐stimulated platelet procoagulant activities

M. Furman, A. Michelson, K. Winters, 2008 .

Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood.

W. Willett, M. Stampfer, C. Hennekens, 1986, The American journal of medicine.

In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel.

M. Mazzeffi, Kenichi A. Tanaka, F. Szlam, 2013, Thrombosis research.

Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.

Masafumi Ueno, D. Angiolillo, F. Franchi, 2014, Journal of the American College of Cardiology.

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

M. Effron, N. Curzen, D. Angiolillo, 2014, Journal of the American College of Cardiology.

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.

E. Antman, E. Braunwald, S. Murphy, 2009, European heart journal.

P2Y12 Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity

M. Berny-Lang, A. Michelson, A. L. Frelinger, 2013, Journal of the American Heart Association.

Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E–Deficient Mice

J. Jakubowski, M. Mizuno, A. Sugidachi, 2017, TH Open.

Platelet function normalization after a prasugrel loading‐dose: time‐dependent effect of platelet supplementation

V. Fuster, J. Badimón, C. Giannarelli, 2013, Journal of thrombosis and haemostasis : JTH.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

R. Kelly, K. Winters, P. Kothare, 2010, Clinical therapeutics.

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects

K. Winters, P. Kothare, J. Jakubowski, 2010, European Journal of Clinical Pharmacology.

Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis*

R. L. Grubbs, Yun-Fei Chen, J. Jakubowski, 2004, Critical care medicine.

Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia

J. Jakubowski, M. Mizuno, A. Sugidachi, 2016, Journal of the American Heart Association.

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

A. Siegbahn, L. Wallentin, T. Jernberg, 2006, European heart journal.

A Model of Controlled Acute Hyperglycemia in Rats: Effects of Insulin and Glucagon-Like Peptide-1 Analog

Yun-Fei Chen, J. Jakubowski, S. Engle, 2006, Journal of Pharmacology and Experimental Therapeutics.

Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects

K. Winters, C. Ernest, J. Jakubowski, 2008, Pharmacotherapy.

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.

L. Wallentin, K. Winters, J. Jakubowski, 2007, Cardiovascular drug reviews.

The natural history of endothelial structure and function in arterialized vein grafts.

J. Jakubowski, H. Bush, D. Deykin, 1986, Journal of vascular surgery.

Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome.

D. Prabhakaran, P. Armstrong, H. White, 2017, Clinical chemistry.

Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrel.

J. Jakubowski, M. Mizuno, A. Sugidachi, 2015, Thrombosis research.

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.

K. Winters, J. Jakubowski, J. Brandt, 2007, British journal of clinical pharmacology.

Prasugrel 5 mg inhibits platelet P-selectin and GPIIb–IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients

L. Truedsson, D. Erlinge, K. Winters, 2016, Journal of Thrombosis and Thrombolysis.

Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease

A. Siegbahn, L. Wallentin, S. James, 2008, Thrombosis and Haemostasis.

Novel findings from the multinational DOVE study on geographic and age‐related differences in pain perception and analgesic usage in children with sickle cell anaemia

D. Manwani, J. Jakubowski, J. Kanter, 2019, British journal of haematology.

Population Pharmacokinetic and Exposure–Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia

J. Jakubowski, D. Small, B. Moser, 2018, Clinical Pharmacokinetics.

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

D. Erlinge, D. Alexopoulos, D. Angiolillo, 2017, American Journal of Cardiovascular Drugs.

Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients

S. James, D. Erlinge, D. Angiolillo, 2013, Journal of Thrombosis and Thrombolysis.

Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.

T. Lindahl, D. Foley, Junxiang Luo, 2013, Journal of the American College of Cardiology.

Beyond platelet functional testing: value in the aggregate.

J. Jakubowski, 2011, Biomarkers in medicine.

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.

J. Jakubowski, A. Sugidachi, Y. Niitsu, 2005, Seminars in thrombosis and hemostasis.

Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.

Deepak L. Bhatt, D. Prabhakaran, P. Armstrong, 2016, Journal of the American College of Cardiology.

The Effect of Cyp2c19 Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Prasugrel 5-mg, Prasugrel 10-mg and Clopidogrel 75-mg in Patients with Coronary Artery Disease Gurbel Cyp2c19 Genetics in Generations and Feather

T. Lindahl, S. James, D. Erlinge, 2022 .

Thienopyridyl and Direct‐Acting P2Y12 Receptor Antagonist Antiplatelet Drugs

J. Jakubowski, A. Sugidachi, 2012 .

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

K. Winters, J. Jakubowski, J. Brandt, 2008, Platelets.

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects

K. Winters, C. Ernest, J. Jakubowski, 2009, Current medical research and opinion.

Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis

K. Winters, G. Weerakkody, J. Jakubowski, 2007, Journal of cardiovascular pharmacology and therapeutics.

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.

D. Prabhakaran, P. Armstrong, H. White, 2012, JAMA.

An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates

R. Jordan, M. Furman, M. Mascelli, 2002, Thrombosis and Haemostasis.

The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data

M. Effron, P. Kulkarni, Junxiang Luo, 2011, Journal of cardiovascular pharmacology.

Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel

E. Antman, E. Braunwald, C. McCabe, 2011, Thrombosis and Haemostasis.

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

J. Badimón, M. Effron, B. Baker, 2011, European heart journal.

A Comparison of the VerifyNow P2Y12 Point-of-Care Device and Light Transmission Aggregometry to Monitor Platelet Function with Prasugrel and Clopidogrel: An Integrated Analysis

Junxiang Luo, K. Winters, J. Jakubowski, 2010, Journal of cardiovascular pharmacology.

The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

S. Heptinstall, J. Jakubowski, N. Dovlatova, 2008, Journal of thrombosis and haemostasis : JTH.

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor

A. Michelson, A. L. Frelinger, A. J. Gerrits, 2017, Journal of thrombosis and haemostasis : JTH.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry

K. Winters, J. Jakubowski, J. Brandt, 2007, Thrombosis and Haemostasis.

Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A2.

R. Kramer, J. Jakubowski, J. A. Jakubowski, 1988, Biochimica et biophysica acta.

Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness.

R. L. Grubbs, Yun-Fei Chen, J. Jakubowski, 2004, The Journal of surgical research.

Is CABG Superior to DES for Repeat Revascularization in Patients With Isolated Proximal LAD Disease?

D. Angiolillo, F. Franchi, F. Rollini, 2022 .

Ionophore-induced metabolism of phospholipids and eicosanoid production in porcine aortic endothelial cells: selective release of arachidonic acid from diacyl and ether phospholipids.

J. Jakubowski, D. Deykin, M. Brown, 1987, Biochimica et biophysica acta.

FoxA2 Involvement in Suppression of Protein C, an Outcome Predictor in Experimental Sepsis

R. L. Grubbs, J. Jakubowski, B. Grinnell, 2006, Clinical and Vaccine Immunology.

Altered arachidonic acid metabolism and platelet size in atopic subjects.

J. Jakubowski, D. Deykin, C. Audera, 1988, Clinical immunology and immunopathology.

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.

A. Siegbahn, L. Wallentin, S. James, 2009, American heart journal.

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.

M. Hashimoto, J. Jakubowski, T. Isobe, 2008, European journal of pharmacology.

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects

K. Winters, G. Weerakkody, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor

J. Jakubowski, T. Isobe, T. Ogawa, 2005, Thrombosis and Haemostasis.

Thrombin-induced phosphorylation and activation of Ca(2+)-sensitive cytosolic phospholipase A2 in human platelets.

J. Manetta, R. Kramer, P. Hyslop, 1993, The Journal of biological chemistry.

Elevated glucose alters eicosanoid release from porcine aortic endothelial cells.

J. Jakubowski, D. Deykin, M. Brown, 1988, The Journal of clinical investigation.

Incorporation and redistribution of arachidonic acid in diacyl and ether phospholipids of bovine aortic endothelial cells.

J. Jakubowski, D. Deykin, H. Wey, 1986, Biochimica et biophysica acta.

The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.

T. Nolin, D. Kereiakes, B. Baker, 2013, Journal of the American College of Cardiology.

Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.

J. Jakubowski, H. Bush, D. Nabseth, 1986, Archives of surgery.

A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.

K. Winters, A. Frelinger, S. Jurcevic, 2013, British journal of clinical pharmacology.

Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification

B. Baker, D. Angiolillo, J. Jakubowski, 2014, Journal of thrombosis and haemostasis : JTH.

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia

Brendan E. Smith, M. Heeney, D. Rees, 2016, Thrombosis and Haemostasis.

A Model of Controlled Acute Hyperglycemia in Rats: Effects of Insulin and GLP-1 Analog

Yun-Fei Chen, J. Jakubowski, S. Engle, 2005 .

Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y12 receptor when interacting with antagonists

S. Kunapuli, J. Jakubowski, J. A. Jakubowski, 2009, Journal of thrombosis and haemostasis : JTH.

Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen.

D. Witcher, T. Martin, W. Liles, 2005, The Journal of infectious diseases.

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.

M. Price, B. Baker, D. Angiolillo, 2012, Journal of the American College of Cardiology.

Edinburgh Explorer Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes

Deepak L. Bhatt, P. Armstrong, H. White, 2018 .

Effect of ethanol on low density lipoprotein and platelet composition

J. Barboriak, J. Jakubowski, N. Rencricca, 1991, Lipids.

Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y12 antagonism

J. Jakubowski, A. Sugidachi, Chunmei Zhou, 2011, Platelets.

Modification of human platelet function by a diet enriched in saturated or polyunsaturated fat.

J. Jakubowski, N. Ardlie, 1978, Atherosclerosis.

Favorable balance of prostacyclin and thromboxane A2 improves early patency of human in situ vein grafts.

J. Jakubowski, H. Bush, D. Deykin, 1984, Journal of vascular surgery.

Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)

J. Badimón, M. Effron, B. Baker, 2009 .

Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro

R. Storey, J. Jakubowski, H. Judge, 2016, Platelets.

A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease: Results of the SWAP-2 Study

M. Effron, N. Curzen, P. Gurbel, 2013 .

Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin

J. Maraganore, J. Jakubowski, 1990 .

Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.

J. Maraganore, J. Jakubowski, 1990, Blood.

Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y12 inhibition

P. Barragan, Shinji Yamaguchi, J. Jakubowski, 2011, Thrombosis and Haemostasis.

Effect of streptozotocin-induced diabetes on prostaglandin production by rat cerebral microvessels.

J. Jakubowski, D. Deykin, H. Wey, 1986, Thrombosis research.

Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation

J. Jakubowski, M. Mizuno, A. Sugidachi, 2013, Thrombosis and Haemostasis.

Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats

M. Hashimoto, Shinji Yamaguchi, J. Jakubowski, 2011, Journal of cardiovascular pharmacology.

The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin

M. Furman, A. Michelson, K. Winters, 2007, Thrombosis and Haemostasis.

Quantitative detection of platelet GPIIb‐IIIa receptor antagonist activity using a flow cytometric method

L. Green, J. Jakubowski, S. Um, 1998, Journal of clinical laboratory analysis.

Activation of Ca(2+)-sensitive cytosolic phospholipase A2 (cPLA2) in human platelets.

R. Kramer, J. Jakubowski, E. Roberts, 1997, Advances in experimental medicine and biology.

Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study

B. Ogutu, M. Heeney, D. Rees, 2016, Journal of clinical medicine.

Cumulative antiplatelet effect of low‐dose enteric coated aspirin

M. Stampfer, J. Jakubowski, D. Deykin, 1985, British journal of haematology.

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.

A. Siegbahn, L. Wallentin, S. James, 2007, European heart journal.

Fas ligand‐induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue

D. Witcher, J. Jakubowski, A. Glasebrook, 2003, Immunology.

The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.

M. Hashimoto, J. Jakubowski, T. Isobe, 2007, Biochemical pharmacology.

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

K. Winters, G. Weerakkody, J. Jakubowski, 2006, Journal of cardiovascular pharmacology.

Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.

J. D. Frank, G. F. Smith, J. Jakubowski, 1992, The Journal of pharmacology and experimental therapeutics.

Effect of Chronic Low Dose Aspirin on Platelet and Vascular Eicosanoid Metabolism in Nonhuman Primates (Macaca fascicularis)

J. Jakubowski, H. Bush, D. Deykin, 1987, Arteriosclerosis.

PERIrPHERAL VASCULA 1 R DISEASE Beneficial elfect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator

J. Jakubowski, H. Bush, D. Deykin, 2005 .

Human group II 14 kDa phospholipase A2 activates human platelets.

R. Kramer, J. Jakubowski, K. Clemetson, 1997, The Biochemical journal.

Further observations on the effects of dietary fatty acid composition on platelet reactivity and blood coagulation in man and the influence of methodology on findings.

J. Jakubowski, F. J. Morgan, C. Chesterman, 1982, Atherosclerosis.

Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.

J. Jakubowski, M. Mizuno, A. Sugidachi, 2014, Thrombosis research.

The effect of hypercholesterolaemia on the lipid composition and ability of human platelets to accumulate cyclic AMP.

P. Nestel, J. Jakubowski, N. Ardlie, 1980, Prostaglandins and medicine.

Acute postprandial lipaemia does not influence the in vivo activity of human platelets.

J. Jakubowski, F. J. Morgan, C. Chesterman, 1985, Thrombosis research.

Platelet Activation and Inhibition iN Sickle cell disease (PAINS) study

M. Berny-Lang, A. Michelson, A. Frelinger, 2012, Platelets.

Absence of "rebound" platelet hyperreactivity following cessation of prasugrel

K. Winters, J. Jakubowski, Y. Li, 2011, Thrombosis and Haemostasis.

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease

K. Winters, A. Frelinger, S. Jurcevic, 2015, Platelets.

Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.

D. Faigel, M. Stampfer, J. Jakubowski, 1986, The Journal of laboratory and clinical medicine.

Effect of membrane cholesterol on phospholipid metabolism in thrombin-stimulated platelets. Enhanced activation of platelet phospholipase(s) for liberation of arachidonic acid.

R. Kramer, J. Jakubowski, D. Deykin, 1982, The Journal of biological chemistry.

Nonclinical Assessment of Carcinogenic Risk and Tumor Growth Enhancement Potential of Prasugrel, a Platelet-Inhibiting Therapeutic Agent

A. Sanbuissho, P. Iversen, L. Buckley, 2012, International journal of toxicology.

The pathophysiology and clinical relevance of platelet heterogeneity.

C. Thompson, J. Jakubowski, C. Thompson, 1988, Blood.

Production Of Thromboxane B2 By Platelets Is Related To Their Density

T. Martin, J. Jakubowski, D. Penington, 1981 .

Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2.

R. Cohen, J. Jakubowski, B. Tesfamariam, 1989, The American journal of physiology.

Factors affecting human platelet function in relation to atherosclerosis

J. Jakubowski, 1980 .

Evidence for the mechanism by which eicosapentaenoic acid inhibits human platelet aggregation and secretion - implications for the prevention of vascular disease.

J. Jakubowski, J A Jakubowski, N G Ardlie, 1979, Thrombosis research.

Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia

S. Adjei, T. Agbenyega, M. Heeney, 2017, Clinical trials.

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

B. Ogutu, T. Agbenyega, M. Heeney, 2016, The New England journal of medicine.

Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y12 blockade and influence of anticoagulant

A. Rechner, J. Jakubowski, P. Harrison, 2012, Platelets.

In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

J. Jakubowski, J. Mitchell, N. Kirkby, 2011, Journal of thrombosis and haemostasis : JTH.

Arachidonic acid metabolism by platelets of differing size

C. Thompson, J. Jakubowski, D. Deykin, 1983, British journal of haematology.

The pericardium as a source of prostacyclin in the dog, ox and rat.

T. Martin, G. Dusting, J. Jakubowski, 1982, Prostaglandins.

Early healing after carotid endarterectomy: effect of high- and low-dose aspirin on thrombosis and early neointimal hyperplasia in a nonhuman primate model.

J. Jakubowski, H. Bush, J. Sentissi, 1988, Journal of vascular surgery.

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.

K. Winters, Lei-Bin Shen, R. Kelly, 2012, British journal of clinical pharmacology.

Luminal release of prostacyclin and thromboxane A2 by arteries distal to small-caliber prosthetic grafts.

J. Jakubowski, H. Bush, D. Deykin, 1984, Circulation.

INACTIVATION OF PROSTACYCLIN (PGI2) BY ERYTHROCYTES

C. Thompson, J. Jakubowski, D. Deykin, 1983, British journal of haematology.

Study of plasma protein C and inflammatory pathways: biomarkers for dimethylnitrosamine-induced liver fibrosis in rats.

Yun-Fei Chen, G. Sandusky, J. Jakubowski, 2007, European journal of pharmacology.

Acute Hyperglycemia Induced by Ketamine/Xylazine Anesthesia in Rats: Mechanisms and Implications for Preclinical Models

J. Jakubowski, Joy K Saha, Jinqi Xia, 2005, Experimental biology and medicine.

arachidonic acid metabolism, and plasma prostacyclin levels1

D. Faigel, M. Stampfer, J. Jakubowski, 1988 .

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

K. Winters, J. Jakubowski, J. Brandt, 2006, Platelets.

Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation.

J. Maraganore, L. Harker, B. Savage, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Neointimal hyperplasia occurring after carotid endarterectomy in a canine model: effect of endothelial cell seeding vs. perioperative aspirin.

J. Jakubowski, H. Bush, J. Hayes, 1987, Journal of vascular surgery.

Platelet size as a determinant of platelet function.

C. Thompson, P. G. Quinn, J. Jakubowski, 1983, The Journal of laboratory and clinical medicine.

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.

L. Jennings, D. Phillips, J. Jakubowski, 1997, Circulation.

Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently

K. Winters, C. Ernest, J. Jakubowski, 2007, Clinical pharmacology and therapeutics.

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

K. Winters, C. Ernest, J. Jakubowski, 2007, Journal of cardiovascular pharmacology.

Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.

K. Winters, M. Warner, G. Weerakkody, 2007, The American journal of cardiology.

The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite

K. Hagihara, M. Hashimoto, J. Jakubowski, 2007, Journal of thrombosis and haemostasis : JTH.

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

K. Winters, S. Wiviott, G. Weerakkody, 2007, American heart journal.

TRITON and Beyond: New Insights into the Profile of Prasugrel

D. Erlinge, J. Riesmeyer, J. Jakubowski, 2011, Cardiovascular therapeutics.

Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel

K. Winters, J. Jakubowski, N. Farid, 2010, Clinical pharmacokinetics.

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humans

K. Winters, J. Jakubowski, J. Brandt, 2006, Platelets.

Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements

H. White, S. Gregory, R. Becker, 2020, Scientific Reports.

A Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic Rats

J. Jakubowski, M. Mizuno, A. Sugidachi, 2016, PloS one.

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

A. Siegbahn, L. Wallentin, S. James, 2008, Journal of the American College of Cardiology.

Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.

D. Angiolillo, F. Rollini, T. Bass, 2015, Journal of the American College of Cardiology.

Activated protein C modulates chemokine response and tissue injury in experimental sepsis.

J. Jakubowski, B. Grinnell, J. G. Heuer, 2008, Advances in experimental medicine and biology.

The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.

S. James, D. Erlinge, D. Angiolillo, 2014, Thrombosis research.

Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in mice.

J. Jakubowski, M. Mizuno, A. Sugidachi, 2015, Thrombosis research.

Regulation of Functionally Active P2Y12 ADP Receptors by Thrombin in Human Smooth Muscle Cells and the Presence of P2Y12 in Carotid Artery Lesions*

J. Fischer, K. Schrör, B. Rauch, 2010, Arteriosclerosis, thrombosis, and vascular biology.

AS-248: Prasugrel and Clopidogrel in Chinese CYP2C19 Allelic Variants following Maintenance Doses

R. Kelly, Lei-Bin Shen, J. Jakubowski, 2009 .

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

K. Winters, J. Jakubowski, J. Brandt, 2009, Platelets.

Interaction of Ethanol, Prostacyclin, and Aspirin in Determining Human Platelet Reactivity in Vitro

J. Jakubowski, D. Deykin, R. Vaillancourt, 1988, Arteriosclerosis.

Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.

D. Faigel, M. Stampfer, J. Jakubowski, 1988, American Journal of Clinical Nutrition.

RECOVERY OF PLATELET FUNCTION FOLLOWING DISCONTINUATION OF PRASUGREL OR CLOPIDOGREL MAINTENANCE DOSING IN ASPIRIN-TREATED SUBJECTS WITH STABLE CORONARY DISEASE: THE RECOVERY TRIAL

M. Price, B. Baker, D. Angiolillo, 2011 .

Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus

D. Angiolillo, F. Rollini, T. Bass, 2016, Thrombosis and Haemostasis.

Ca(2+)-sensitive cytosolic phospholipase A2 (cPLA2) in human platelets.

J. Manetta, R. Kramer, J. Sportsman, 1993, Journal of lipid mediators.

Tantalus revisited--the search for the ideal anti-thrombotic dose of aspirin.

D. Faigel, M. Stampfer, J. Jakubowski, 1987, Transactions of the American Clinical and Climatological Association.

The role of serotonin (5HT2) receptor blockade in myocardial reperfusion injury: effects of LY53857 in a canine model of myocardial infarction.

P. J. Simpson, J. Jakubowski, J. K. Smallwood, 1991, The Journal of pharmacology and experimental therapeutics.

Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction.

C. Thompson, J. Jakubowski, D. Deykin, 1985, The Journal of laboratory and clinical medicine.

Effects of hyperglycemia and insulin therapy on outcome in a hyperglycemic septic model of critical illness.

R. L. Grubbs, Yun-Fei Chen, J. Jakubowski, 2006, The Journal of trauma.

Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.

J. Jakubowski, H. Bush, D. Deykin, 1986, Circulation.

Prasugrel 5mg in the very elderly is non-inferior to prasugrel 10mg in non-elderly patients : the generations trial, a pharmacodynamic (PD) study in stable CAD patients

T. Lindahl, S. James, D. Erlinge, 2012 .

Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E–Deficient Mice

J. Jakubowski, M. Mizuno, A. Sugidachi, 2017, TH Open.

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

M. Effron, N. Curzen, D. Angiolillo, 2014, Journal of the American College of Cardiology.

Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?

E. Ohman, J. Cornel, K. Huber, 2012, Thrombosis and Haemostasis.

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.

L. Wallentin, K. Winters, J. Jakubowski, 2007, Cardiovascular drug reviews.

Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease.

A. Chishti, A. Frelinger, A. J. Gerrits, 2017, Thrombosis research.

The Biology of Platelet Volume Heterogeneity

J. Jakubowski, R. Monroy, R. Skelly, 1990 .

Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in mice.

J. Jakubowski, M. Mizuno, A. Sugidachi, 2015, Thrombosis research.

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.

M. Price, B. Baker, D. Angiolillo, 2012, Journal of the American College of Cardiology.

Lack of rebound in platelet reactivity following cessation of prasugrel or clopidogrel in type 2 diabetes mellitus patients with coronary artery disease: insights from OPTIMUS-3

M. Effron, B. Baker, D. Angiolillo, 2010 .

The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.

T. Nolin, D. Kereiakes, B. Baker, 2013, Journal of the American College of Cardiology.

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

K. Winters, J. Jakubowski, J. Brandt, 2009, Platelets.

T. Lindahl, D. Foley, Junxiang Luo, 2013, Journal of the American College of Cardiology.

Pharmacokinetics and pharmacodynamics of prasugrel 5 mg in low body weight patients and prasugrel 10 mg in higher body weight patients

S. James, D. Erlinge, D. Angiolillo, 2012 .